In recently reported case studies, nemolizumab, approved for two indications associated with itch, has been reported to be ...

At a recent FDA panel on SSRIs in pregnancy, the chair suggested rising antidepressant use may be contributing to — not ...

The European Medicines Agency determined testing failed to prove Elevidys’ benefit and issued a negative opinion that could ...

A recent study characterized the expression of ADC targets across ovarian cancer histotypes. Findings suggest ...

Number 5: Sarfaraz K. Niazi, PhD, argues that the FDA can accelerate biosimilar entry by changing guidance under the ...

Regulatory consultant’Rourke argues why the EU's current novel food regulation is slow, and what it can learn from competitors.

The FDA may remove the warning labels on hormone replacement therapies used to treat the symptoms of menopause. Doctors say ...

There was a lot of excitement when Tepezza became the first drug approved for the treatment of thyroid eye disease in January ...

The move would bring down costs for consumers on several medicines by cutting out middlemen like PBMs and their associated costs. More stories look at surprise fees for patients, a plan to reduce ...

If you collect the data today, what can you read from it five years from now because the technology is advancing so quickly?” ...

Roche’s move came against a backdrop of wider industry retreat from gene therapy, with Pfizer pulling its FDA-approved ...